CD79B and primary central nervous system lymphoma: Interestingly, previous studies involving large cohorts of PCNSL patients receiving a uniform chemotherapy regimen of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) indicated that the MYD88 L265P and CD79B Y196 mutations were associated with prognosis (Nakamura et al., 2016; Nayyar et al., 2019).